MODIFIED PRO RE NATA REGIMEN OF BROLUCIZUMAB IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
In our study, pro re nata regimen of brolucizumab without loading phase seems to be an effective treatment option in treatment-naive neovascular age-related macular degeneration patients, with intraocular inflammation rate similar to the one reported in trials and lower number of injections.
Authors
- Giuseppe Querques (ORCID: https://orcid.org/0000-0002-3292-9581)
- Giovanni Fossati (ORCID: https://orcid.org/0000-0002-3374-8539)
- Francesco Santoru (ORCID: https://orcid.org/0000-0002-7463-2479)
- Alessandro Feo (ORCID: https://orcid.org/0009-0005-2999-6782)
- Carlo La Spina (ORCID: https://orcid.org/0000-0002-0733-9846)
- Piero Zollet (ORCID: https://orcid.org/0000-0002-5892-7533)
- Claudio Panico (ORCID: https://orcid.org/0000-0002-8537-9325)
- Edoardo Panico
- Claudia Del Turco (ORCID: https://orcid.org/0000-0002-1357-2548)
- Myrta Lippera (ORCID: https://orcid.org/0000-0002-5027-3483)
- Mario Rosario Romano (ORCID: https://orcid.org/0000-0003-0348-0532)
Institutions
- Humanitas University (IT)
- Vita-Salute San Raffaele University (IT)
- Manchester Royal Eye Hospital (GB)
- Ospedale Humanitas Gradenigo (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
Publication Details
- Journal
- Retinal Cases & Brief Reports
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1097/icb.0000000000001692
- Citations
- 1
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.47